Brief: 2Seventy Bio And Jw Therapeutics Announce Strategic Partnership To Accelerate The Research And Development Of T Cell-Based Immunotherapies
27/10/2022 12:55
Oct 27 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* 2SEVENTY BIO AND JW THERAPEUTICS ANNOUNCE STRATEGIC
PARTNERSHIP
TO ACCELERATE THE RESEARCH AND DEVELOPMENT OF T CELL-BASED
IMMUNOTHERAPIES
Source text for Eikon: ID:nBw5QJvcva
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License